You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
| Title |
The Carbomer-Lecithin Adjuvant Adjuplex Has Potent Immunoactivating Properties and Elicits Protective Adaptive Immunity against Influenza Virus Challenge in Mice
|
|---|---|
| Published in |
mSphere, July 2015
|
| DOI | 10.1128/cvi.00736-14 |
| Pubmed ID | |
| Authors |
Frank Wegmann, Amin E. Moghaddam, Torben Schiffner, Kate H. Gartlan, Timothy J. Powell, Rebecca A. Russell, Matthijs Baart, Emily W. Carrow, Quentin J. Sattentau |
| Abstract |
The continuing discovery and development of adjuvants for vaccine formulation is important to safely increase potency and/or reduce antigen dose of existing vaccines, and tailor the adaptive immune response to newly-developed vaccines. Adjuplex™ is a novel adjuvant platform based on purified lecithin and carbomer homopolymer. Here we analyzed the adjuvant activity of Adjuplex™ in mice for the soluble hemagglutinin (HA) glycoprotein of influenza A. Titration of Adjuplex™ revealed an optimal dose of 1% for immunogenicity, eliciting high titers of HA-specific HA, but inducing no significant weight loss. At this dose, Adjuplex™ completely protected mice from an otherwise lethal influenza challenge, and was at least as effective as adjuvants MPL and alum in preventing disease. Adjuplex™ elicited a balanced Th1/Th2-type immune response with accompanying cytokines, and triggered antigen-specific CD8(+) T cell proliferation. Use of the peritoneal inflammation model revealed that Adjuplex™ recruited dendritic cells (DCs), monocytes and neutrophils in the context of innate cytokine and chemokine secretion. Adjuplex™ neither triggered classical maturation of DCs nor activated a pathogen recognition receptor (PRR)-expressing NFκB reporter cell line, suggesting a mechanism of action different from that reported for classical pathogen-associated molecular pattern (PAMP)-activated innate immunity. Taken together, these data reveal Adjuplex™ as a potent and well-tolerated adjuvant with application for subunit vaccines. |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Australia | 1 | 25% |
| United States | 1 | 25% |
| United Kingdom | 1 | 25% |
| Unknown | 1 | 25% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 50% |
| Science communicators (journalists, bloggers, editors) | 1 | 25% |
| Scientists | 1 | 25% |
Mendeley readers
The data shown below were compiled from readership statistics for 38 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 38 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 7 | 18% |
| Student > Ph. D. Student | 6 | 16% |
| Student > Bachelor | 4 | 11% |
| Other | 3 | 8% |
| Student > Doctoral Student | 2 | 5% |
| Other | 5 | 13% |
| Unknown | 11 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 7 | 18% |
| Immunology and Microbiology | 6 | 16% |
| Biochemistry, Genetics and Molecular Biology | 4 | 11% |
| Medicine and Dentistry | 4 | 11% |
| Chemistry | 2 | 5% |
| Other | 4 | 11% |
| Unknown | 11 | 29% |